Breaking News Instant updates and real-time market news.

CELG

Celgene

$85.85

0.25 (0.29%)

10:07
07/13/18
07/13
10:07
07/13/18
10:07

Juno's lisocabtagene maraleucel granted FDA orphan drug designation

Juno Therapeutics' lisocabtagene maraleucel was granted FDA orphan designation as a treatment of primary mediastinal large B-cell lymphoma, according to a post to the FDA website. Juno is a unit of Celgene. Reference Link

  • 26

    Jul

CELG Celgene
$85.85

0.25 (0.29%)

07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Neutral
Celgene raised prices on both Revlimid and Pomalyst by 5%, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Wolters Kluwer Health reports that Celgene increased its prices for Revlimid and Pomalyst by 5%, effective yesterday. The analyst, who pointed out that this is the first increase since October 2017 for both drugs, said the price hikes should provide some tailwind to Celgene's second half results. He maintains his Neutral rating on Celgene shares.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/12/18
PIPR
07/12/18
NO CHANGE
Target $95
PIPR
Neutral
PTAB decision on Gilenya positive for Celgene, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.

TODAY'S FREE FLY STORIES

KRA

Kraton

$25.50

-0.77 (-2.93%)

06:26
01/24/19
01/24
06:26
01/24/19
06:26
Recommendations
Kraton analyst commentary  »

Kraton shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCMLY

LafargeHolcim

$0.00

(0.00%)

06:25
01/24/19
01/24
06:25
01/24/19
06:25
Downgrade
LafargeHolcim rating change  »

LafargeHolcim downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESSYY

Essity

$0.00

(0.00%)

06:23
01/24/19
01/24
06:23
01/24/19
06:23
Initiation
Essity initiated  »

Essity initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$8.03

0.3 (3.88%)

06:23
01/24/19
01/24
06:23
01/24/19
06:23
Periodicals
PG&E says wildfire prevention may cost up to $150B, Reuters reports »

PG&E, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONXXF

Ontex Group

$0.00

(0.00%)

06:21
01/24/19
01/24
06:21
01/24/19
06:21
Initiation
Ontex Group initiated  »

Ontex Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

06:20
01/24/19
01/24
06:20
01/24/19
06:20
Periodicals
Google to appeal $57M fine for breaching GDPR rules, Business Insider reports »

Google has confirmed it…

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

AAPL

Apple

$153.91

0.61 (0.40%)

, SSNLF

Samsung

$0.00

(0.00%)

06:18
01/24/19
01/24
06:18
01/24/19
06:18
Periodicals
Samsung exec poached by Apple to lead battery development, Bloomberg reports »

Apple (AAPL) has poached…

AAPL

Apple

$153.91

0.61 (0.40%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

EADSY

Airbus

$0.00

(0.00%)

06:14
01/24/19
01/24
06:14
01/24/19
06:14
Periodicals
Airbus CEO issues warning about jobs in event of no-deal Brexit, Reuters reports »

Airbus CEO Tom Enders…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$30.55

1 (3.38%)

06:11
01/24/19
01/24
06:11
01/24/19
06:11
Periodicals
Sinclair Broadcast hires liberal commentator Ameshia Cross, WSJ reports »

Sinclair Broadcast, known…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$91.51

-0.13 (-0.14%)

06:10
01/24/19
01/24
06:10
01/24/19
06:10
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$15.22

-0.18 (-1.17%)

06:08
01/24/19
01/24
06:08
01/24/19
06:08
Downgrade
CenturyLink rating change  »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 25

    Feb

ASND

Ascendis Pharma

$73.16

-0.47 (-0.64%)

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Upgrade
Ascendis Pharma rating change  »

Ascendis Pharma upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Recommendations
F5 Networks analyst commentary  »

F5 Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTH

Duluth Holdings

$20.41

0.425 (2.13%)

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Upgrade
Duluth Holdings rating change  »

Duluth Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:06
01/24/19
01/24
06:06
01/24/19
06:06
Hot Stocks
Nissan plans April investor meeting to oust Ghosn from board »

Nissan (NSANY) announced…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$13.27

-0.07 (-0.52%)

, BDRBF

Bombardier

$0.00

(0.00%)

06:05
01/24/19
01/24
06:05
01/24/19
06:05
Hot Stocks
Bombardier to acquire Global 7500 aircraft wing program from Triumph Group »

Bombardier (BDRBF)…

TGI

Triumph Group

$13.27

-0.07 (-0.52%)

BDRBF

Bombardier

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

RNSDF

Renault

$0.00

(0.00%)

06:05
01/24/19
01/24
06:05
01/24/19
06:05
Periodicals
Renault's board asked to name Senard, Bollare to replace Ghosn, Reuters says »

Renault's board will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$9.04

0.195 (2.20%)

06:03
01/24/19
01/24
06:03
01/24/19
06:03
Periodicals
Deutsche Bank gets inquiry from House panels on Trump ties, Reuters reports »

Deutsche Bank has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$99.46

-1.16 (-1.15%)

06:03
01/24/19
01/24
06:03
01/24/19
06:03
Downgrade
Post Holdings rating change  »

Post Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 01

    Feb

MTL

Mechel

$2.50

0.075 (3.10%)

06:01
01/24/19
01/24
06:01
01/24/19
06:01
Hot Stocks
Mechel launches steel trade online store »

Mechel reports launching…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNSDF

Renault

$0.00

(0.00%)

, NSANY

Nissan

$0.00

(0.00%)

06:01
01/24/19
01/24
06:01
01/24/19
06:01
Periodicals
Carlos Ghosn resigns as head of Renault, Bloomberg reports »

Carlos Ghosn has resigned…

RNSDF

Renault

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URGN

UroGen Pharma

$45.90

-7.6 (-14.21%)

06:00
01/24/19
01/24
06:00
01/24/19
06:00
Syndicate
UroGen Pharma 3.66M share Secondary priced at $41.00 »

Goldman Sachs, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

GRBK

Green Brick

$8.13

0.13 (1.63%)

06:00
01/24/19
01/24
06:00
01/24/19
06:00
Initiation
Green Brick initiated  »

Green Brick initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$51.39

6.01 (13.24%)

05:59
01/24/19
01/24
05:59
01/24/19
05:59
Syndicate
eHealth 2.4M share Secondary priced at $48.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

INCY

Incyte

$75.20

-2.11 (-2.73%)

05:59
01/24/19
01/24
05:59
01/24/19
05:59
Upgrade
Incyte rating change  »

Incyte upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.